Behind a doubling in adjusted EPS sits a more modest picture -- and a dividend streak worth understanding.

When a drugmaker's top product loses patent protection, the dividend usually takes the hit. Four pharma giants are each betting on newer drugs to fill the gap, but how close each one sits to the edge ...

AbbVie's stock has surged nearly 29% this year, but a rising share price compresses the yield even as the dividend keeps growing. Before adding shares for income, consider what the pending Apogee deal ...

Oct 30 (Reuters) - AbbVie raised its annual profit forecast after topping Wall Street expectations for the third quarter on ...

AbbVie stock outperformed S&P 500 with a +16% to 9.41% return since November 2023, despite Humira revenue declining 38% to $8.99 billion. Immunology drugs Skyrizi and Rinvoq grew over 50% ...

Abbvie () has held its Q3 earnings call. Read on for the main highlights of the call. AbbVie delivered a strongly positive third quarter, combining double-digit revenue growth wit ...

Newer therapies must sustain double-digit growth to offset the impact of Humira's patent cliff, a test that shapes the ...

AbbVie ABBV is a dominant player in the immunology space, powered by three blockbuster drugs — Skyrizi, Rinvoq and Humira — which together account for nearly half of its top line. Although the company ...

AbbVie offers a compelling blend of high yield, consistent dividend growth, and strong financials, making it attractive for income-focused investors. The company has successfully transitioned from ...

AbbVie raised its quarterly dividend 5.2% to $1.82 a share on Oct. 30, and Chevron reported third-quarter earnings of $9.9 ...

(Reuters) -AbbVie on Thursday trimmed its 2023 view for declining sales of its flagship arthritis drug Humira despite new competition, as favorable positions on insurance drug coverage lists helped it ...

AbbVie signed a non-exclusive licensing deal with Pfizer for its Humira biosimilar, Nasdaq reports. 1. Pfizer can launch its Humira biosimilar in the U.S. on Nov. 20, 2023. In Europe, Pfizer can ...